^
    1d
    SZ4601: CAR-T Cell Therapy Targeting to CD19 for R/R ALL (clinicaltrials.gov)
    P1/2, N=196, Recruiting, The First Affiliated Hospital of Soochow University | Active, not recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Aug 2024 --> Aug 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    2d
    IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL. (PubMed, Hemasphere)
    In most dual-driver cases, one subtype gene expression signature predominated, consistent with oncogenic hierarchies, but also with the possibility of technical artifacts, which should prompt individual orthogonal validations. IntegrateALL provides an adaptable fully reproducible workflow for molecular B-ALL characterization by systematically integrating genomic drivers and downstream gene regulation.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1) • PAX5 (Paired Box 5) • DUX4 (Double Homeobox 4)
    2d
    A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=26, Not yet recruiting, Memorial Sloan Kettering Cancer Center | Phase classification: P2 --> P1/2 | Initiation date: Mar 2026 --> Jun 2026
    Phase classification • Trial initiation date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule)
    3d
    Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1 trial • IO biomarker
    |
    CD19 (CD19 Molecule)
    4d
    The INFLUENCE Trial: Improve CAR T cell therapy by optimizing fludarabine exposure (2025-523096-34-00)
    P2/3, N=20, Not yet recruiting, Prinses Maxima Centrum voor Kinderoncologie B.V.
    New P2/3 trial
    |
    fludarabine IV
    5d
    Semaphorin 4D (CD100) expression as a predictor for the response to induction therapy in pediatric patients with B-acute lymphoblastic leukemia. (PubMed, Eur J Pediatr)
     PBMCs' Sema4D expression can be considered a potential marker for predicting the response to induction therapy in pediatric patients with B-ALL. So, it may serve to optimize treatment decisions for those patients.
    Journal
    |
    SEMA4D (Semaphorin 4D)
    5d
    Dual-trigger model of CD20 escape: NONO regulation and cryptic splicing induced by transcript overload in pediatric B-ALL. (PubMed, Front Immunol)
    Together, these findings are consistent with a model in which NONO expression and transcript-level dynamics of MS4A1 are associated with CD20 heterogeneity in pediatric B-ALL. These observations may contribute to understanding variability in CD20 expression and antigen availability in pediatric B-ALL.
    Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • MS4A1 (Membrane Spanning 4-Domains A1) • NONO (Non-POU Domain Containing Octamer Binding)
    |
    CD20 positive
    6d
    Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, University of Michigan Rogel Cancer Center
    New P1 trial
    |
    pomalidomide
    7d
    The value of minimal residual disease-guided risk stratification in different subtypes of pediatric B-cell acute lymphoblastic leukemia (PubMed, Zhonghua Er Ke Za Zhi)
    In patients with ETV6::RUNX1 positivity or hyperdiploidy, MRD is less effective in distinguishing between low-risk and intermediate-risk groups but can precisely identify the high-risk group with significantly poorer prognosis. Conversely, in NENH-B-ALL, MRD effectively stratifies patients into low, intermediate, and high-risk categories, demonstrating superior discriminatory power in prognostic stratification.
    Journal • Minimal residual disease
    |
    RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6)
    7d
    Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Feb 2026 --> Sep 2026
    Trial initiation date
    7d
    APHP241013: PREV-CART - A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiotic prophylaxis (AP) in patients treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B cell acute lymphoblastic leukemia or a B cell lymphoma (2025-521571-30-00)
    P2/3, N=228, Not yet recruiting, Assistance Publique Hopitaux De Paris
    New P2/3 trial